No Data
No Data
Barclays Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $16
Barclays analyst Balaji Prasad maintains $Evolus(EOLS.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 46.3% and a total aver
Barclays Reaffirms Their Buy Rating on Evolus (EOLS)
Strong Buy Rating for Evolus Backed by Growth Potential and Market Penetration Prospects
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
Evolus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/21/2024 101.19% HC Wainwright & Co. → $27 Reiterates Buy → Buy 05/08/2024 101.19% HC Wainwright & Co. →
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Korro Bio (KRRO) and Inhibikase Therapeutics (IKT)